GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (NAS:ANIP) » Definitions » 12-1 Month Momentum %

ANI Pharmaceuticals (ANI Pharmaceuticals) 12-1 Month Momentum % : 85.20% (As of Apr. 26, 2024)


View and export this data going back to 1999. Start your Free Trial

What is ANI Pharmaceuticals 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-26), ANI Pharmaceuticals's 12-1 Month Momentum % is 85.20%.

The industry rank for ANI Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:

ANIP's 12-1 Month Momentum % is ranked better than
91.67% of 1116 companies
in the Drug Manufacturers industry
Industry Median: -5.66 vs ANIP: 85.20

Competitive Comparison of ANI Pharmaceuticals's 12-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ANI Pharmaceuticals's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's 12-1 Month Momentum % falls into.



ANI Pharmaceuticals  (NAS:ANIP) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ANI Pharmaceuticals  (NAS:ANIP) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


ANI Pharmaceuticals 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of ANI Pharmaceuticals's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


ANI Pharmaceuticals (ANI Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Executives
Muthusamy Shanmugam director, officer: HEAD OF R&D, COO-NOVITIUM OPS C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Meredith Cook officer: SR. VP, GENERAL COUNSEL & SEC. C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Krista Davis officer: SVP, CHIEF HR OFFICER C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Christopher Mutz officer: HEAD OF RARE DISEASE C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Chad Gassert officer: SVP - CORP. DEV. & STRATEGY C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Ori Gutwerg officer: SVP, GENERICS C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
James G. Marken officer: Vice President, Operations 210 MAIN STREET WEST, C/O BIOSANTE PHARMACEUTICALS, INC., BAUDETTE MN 56623
Matthew J Leonard director 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Meridian Venture Partners Ii Lp 10 percent owner
Nikhil Lalwani director, officer: PRESIDENT & CEO C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Antonio R Pera director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Stephen P. Carey officer: Vice President and CFO C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Jeanne Thoma director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780